New epilepsy drug vormatrigine enters final testing phase
NCT ID NCT07505004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial is testing whether the experimental drug vormatrigine can reduce the frequency of focal seizures in adults with epilepsy. About 300 participants who already take 1 to 3 seizure medications will receive either a low, medium, or high dose of vormatrigine or a placebo daily for 12 weeks. The main goal is to see if vormatrigine leads to a greater reduction in monthly seizures compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vormatrigine
What this could lead to
If successful, this could provide a new treatment option for adults with focal seizures that are not fully controlled by current medications.
What could go wrong
This is a Phase 3 trial, but results may not show a significant benefit over placebo. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Praxis Research Site
RECRUITINGMiami, Florida, 33133, United States
-
Praxis Research Site
RECRUITINGMiami Lakes, Florida, 33016, United States
-
Praxis Research Site
NOT_YET_RECRUITINGNaples, Florida, 34116, United States
-
Praxis Research Site
RECRUITINGMarlboro, New Jersey, 07746, United States
-
Praxis Research Site
RECRUITINGNiagara Falls, New York, 14304, United States
-
Praxis Research Site
RECRUITINGRaleigh, North Carolina, 27607, United States
-
Praxis Research Site
RECRUITINGHouston, Texas, 77058, United States